A subnormal level of BLOOD PLATELETS.
| Excerpt | Reference |
|---|
| "Anaphylactic thrombocytopenia is beyond the control of agents which stimulate the cyclic AMP system, and involves specific mechanism which are not stimulated in platelet-rich plasma." | ( Lefort, J; Vargaftig, BB, 1979) |
| "If thrombocytopenia is detected, platelet aggregation studies are indicated." | ( Bernhard, VM; Garancis, JC; Hussey, C; Towne, JB, 1979) |
| "Thrombocytopenia is an uncommon but serious side effect of the antimicrobial combination of trimethoprim and sulphamethoxazole." | ( Dickson, HG, 1978) |
| "Thrombocytopenia is a rare complication of chlorpropamide therapy." | ( Cunliffe, DJ; Gorst, DW; Palmer, HM, 1977) |
| "Thrombocytopenia is often one of the first signs of vinylchloride disease." | ( Heusermann, U; Stutts, HJ, 1977) |
| "The thrombocytopenia is not due to the associated polycythemia, splenomegaly, or increased blood volume." | ( Birks, JW; Gurney, CW; Klassen, LW, 1975) |
| "Thrombocytopenia is a known complication of human immunodeficiency virus Type-1 (HIV-1) infection, and more data need to be collected on its frequency, severity, and clinical sequelae." | ( Banks, SM; Klein, HG; Merritt, S; Pierce, P; Sloand, EM; Vareldzis, B, 1992) |
| "Thrombocytopenia is one of the manifestations of infection by the human immunodeficiency virus-1 (HIV-1)." | ( Domínguez Castellano, A; González, J; López Pastor, A; Martín, R; Peña, JM; Vázquez, JJ, 1992) |
| "Heparin-induced thrombocytopenia is a common immune-mediated drug reaction that can be complicated by life-threatening arterial thrombosis." | ( Hayward, CP; Kelly, PM; Kelton, JG; Smith, CA; Warkentin, TE, 1992) |
| "Thrombocytopenia is a common adverse effect of heparin therapy." | ( Chong, BH, 1992) |
| "Spurious thrombocytopenia is an infrequent laboratory problem that may be confused with true thrombocytopenia, leading to inappropriate testing to determine the cause of the thrombocytopenia." | ( Brandt, JT; Cunningham, VL, 1992) |
| "Immune thrombocytopenia is a rare complication of progressive systemic sclerosis (PSS)." | ( Kashiwagi, H; Kato, S; Kono, I; Matsui, Y; Natsuda, H; Sakauchi, M; Suzuki, H; Takemura, H; Yamane, K, 1992) |
| "Cyclic thrombocytopenia is a rare disease characterized by cyclic oscillations of platelet counts from very low to normal or higher." | ( Ahn, YS; Harrington, WJ; Horstman, L; Mylvaganam, R; Rocha, R, 1991) |
| "Thrombocytopenia is defined as a decrease in the platelet count to less than 100 x 10(9)/L and it is the most commonly reported drug-induced blood dyscrasia." | ( Brandon, D; Hull, RL, 1991) |
| "Thrombocytopenia is the most serious dose-limiting toxicity of (glycolato-O,O')-diammine platinum (II) (254-S; NSC 375101D), one of the new platinum analogues." | ( Eguchi, K; Fukuda, M; Kojima, A; Morita, M; Nakagawa, K; Ohe, Y; Sasaki, Y; Shinkai, T; Tamura, T; Yamada, K, 1990) |
| "EDTA-induced pseudothrombocytopenia is a laboratory artifact caused in vitro by platelet aggregation, due to IgG or IgM class antibodies reacting with antigenic binding site of the GP IIb glycoprotein." | ( Casati, O; Foresti, V; Parisio, E; Pedretti, D; Tronci, M; Zubani, R, 1990) |
| "Thrombocytopenia is a rare side effect of amphotericin B." | ( Advani, SH; Charak, BS; Gopal, R; Iyer, RS; Rajoor, BG; Saikia, TK, 1990) |
| "Heparin-associated thrombocytopenia is mediated through IgG or IgM immunoglobulin fractions and is believed to be an immune phenomenon, with heparin acting as a hapten." | ( Nand, S; Robinson, JA, 1988) |
| "Pseudothrombocytopenia is an in vitro phenomenon usually associated with anticoagulant (EDTA)-dependent IgG platelet agglutinins." | ( Durie, BG; Hoyt, RH, 1989) |
| "We believe that thrombocytopenia is an important side effect of sustained-release procainamide therapy." | ( Carlson, RJ; Gottlieb, AJ; Meisner, DJ, 1985) |
| "Thrombocytopenia is occasionally caused by rifampicin, when high-doses are given twice-weekly." | ( Lee, CH; Lee, CJ, 1989) |
| "Thrombocytopenia is commonly found in patients with serious infection." | ( Aufses, AH; Benjamin, E; Berger, SR; Gabrielson, GV; Gentili, DR; Iberti, TJ; Rand, JH, 1986) |
| "Gold induced thrombocytopenia is immune mediated, with the production of platelet associated IgG leading to peripheral platelet destruction." | ( Adachi, JD; Bensen, WG; Bianchi, FA; Buchanan, WW; Cividino, A; Craig, GL; Kassam, Y; Kean, WF; Powers, PJ; Rooney, PJ, 1987) |
| "Thrombocytopenia is a common occurrence (20%) in sick neonates, but the causes have not been well studied." | ( Andrew, M; Castle, V; Coates, G; Kelton, JG, 1987) |
| "Heparin-induced thrombocytopenia is the most frequent and the most important idiosyncratic haematological drug reaction." | ( Kelton, JG, 1986) |
| "Amiodarone-induced thrombocytopenia is probably due to delayed hypersensitivity reaction as indicated by the strongly positive lymphocyte stimulation test results using amiodarone." | ( Agmon, J; Ben-Sasson, E; Fuchs, J; Rotenberg, Z; Weinberger, I, 1987) |
| "Thrombocytopenia is a common clinical disorder with a diverse group of etiologies." | ( Sheehan, RG, 1985) |
| "In such cases thrombocytopenia is thus not the result of disseminated intravascular coagulation (D." | ( Katz, J; Levin, J; Lurie, A; Metz, J; Skudowitz, RB, 1973) |
| "Severe cyclic thrombocytopenia is reported in a young woman." | ( Lewis, ML, 1974) |
| "When thrombocytopenia is noted, prompt withdrawal of the drug is required." | ( Ponte, CD, 1983) |
| "Pseudothrombocytopenia is an in vitro phenomenon of platelet agglutination and clumping in the presence of EDTA on the electronical measurement of platelet count." | ( Fujita, T; Isobe, T; Kinoshita, S; Terao, C; Yamaguchi, N, 1983) |
| "Thrombocytopenia is characteristically associated with septicemia and hemolytic uremic syndrome (HUS), a subset of which has been shown to be associated with endotoxemia and shigellosis." | ( Fong, JS; King-Hrycaj, BD, 1983) |
| "Thrombocytopenia is also without effect on either exudate volume or rate of leakage of Sb2S3 in pleurisy induced by intrapleural injection of homologous serum or turpentine." | ( Hurley, JV; Miles, RG, 1983) |
| "Heparin-induced thrombocytopenia is an infrequently suspected adverse drug reaction since its sequelae often mimic the underlying condition for which the drug is being used." | ( Guay, DR; Richard, A, 1984) |
| "The mechanism of thrombocytopenia is not known and it is not clear whether this effect represents a high-frequency idiosyncratic reaction or an overt manifestation of a toxic effect on platelet survival." | ( Brandt, JT; Hermiller, J; Leier, CV; Miller, L; Unverferth, DV, 1984) |
| "2." | ( Gibson, B; Hunter, D; Kelton, JG; Neame, PB, 1982) |
| "Thrombocytopenia is a common serious adverse effect of drug treatment." | ( Barr, R; Bianchi, F; Carter, CJ; Giles, AR; Hirsh, J; Kelton, JG; Meltzer, D; Moore, J; Neame, PB; Powers, PJ; Walker, I; Wilson, WE, 1981) |
| "Thrombocytopenia is usually present in falciparum malaria." | ( Schreiber, W, 1981) |
| "Thrombocytopenia is a common accompaniment of disseminated histoplasmosis." | ( Des Prez, RM; Hawiger, J; Steckley, S; Stroud, RM, 1980) |
| "Cumulative thrombocytopenia is a dose-limiting toxicity of dose-intensive chemotherapy for advanced breast cancer." | ( Chow, C; Cowan, KH; Danforth, D; Denicoff, A; Goldspiel, B; Gossard, M; Jacobson, J; Keegan, P; Miller, L; Noone, MH; O'Shaughnessy, JA; Tolcher, A; Venzon, DJ, 1995) |
| "Thrombocytopenia is a frequent haematologic complication of IL-2 immunotherapy of cancer." | ( Barni, S; Bregani, ER; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rossini, F; Tancini, G, 1995) |
| "Heparin-associated thrombocytopenia is a serious medical problem, especially when the patient requires continued anticoagulation." | ( Chamberlin, JR; Fareed, J; Hoppensteadt, D; Lewis, B; Leya, F; McKiernan, T; Messmore, H; Moran, S; Walenga, JM; Wallis, D, 1995) |
| "Heparin-induced thrombocytopenia is characterized by moderate thrombocytopenia and thrombotic complications, whereas quinine/quinidine-induced thrombocytopenia usually presents with severe thrombocytopenia and bleeding." | ( Bode, AP; Boshkov, LK; Hayward, CP; Kelton, JG; Santos, AV; Sheppard, JA; Warkentin, TE, 1994) |
| "Thrombocytopenia is explained mainly by suppression of thrombocytopoiesis, as established by two independent ways: 1." | ( Aranda, E; Mezzano, D; Pereira, J; Pizarro, M, 1994) |
| "Immune thrombocytopenia is rarely associated with HD and its remission following resection of an accessory spleen is an unusual finding." | ( Calero, MA; García-Suárez, J; Krsnik, I; Perera, F; Pérez-Rus, G; Ricard, MP, 1994) |
| "When thrombocytopenia is diagnosed in horses without clinical evidence of a bleeding tendency, EDTA-dependent pseudothrombocytopenia should be considered." | ( Hinchcliff, KW; Kociba, GJ; Mitten, LA, 1993) |
| "Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses." | ( Alvord, WG; Creekmore, SP; Curti, BD; Fenton, RG; Gause, BL; Holmlund, JT; Janik, JE; Longo, DL; Sharfman, WH; Smith, JW, 1993) |
| "Pseudothrombocytopenia is a phenomenon in which the electronic count shows spuriously low platelet counts in subjects with normal platelet levels." | ( De Caterina, M; Di Maro, G; Formisano, S; Fratellanza, G; Grimaldi, E; Scopacasa, F; Varriale, V, 1993) |
| "Thrombocytopenia is less severe and occurs between days 3 and 8." | ( Brewer, WG; Henry, CJ; Stutler, SA, 1993) |
| "Amrinone-associated thrombocytopenia is thought to result from nonimmune-mediated peripheral platelet destruction." | ( Allen-Webb, EM; McGough, EC; Pappas, JB; Ross, MP, 1993) |
| "Thrombocytopenia is a manifestation of hematopoietic toxicity that, at present, can be treated only with platelet transfusions." | ( Budd, GT, 1996) |
| "Rifampicin-induced thrombocytopenia is reported in three patients with pulmonary tuberculosis." | ( Badakere, SS; Jijina, FF; Mehta, YS; Mohanty, D; Pathare, AV, 1996) |
| "Heparin-induced thrombocytopenia is an immuno-mediated life-threatening side effect of heparin therapy which poses difficulties in diagnosis and major therapeutic problems." | ( Claeys, L; Ehringer, H; Huk, I; Koppensteiner, R; Kyrle, PA; Minar, E; Muhm, M; Polterauer, P; Stümpflen, A, 1997) |
| "Pseudothrombocytopenia is a laboratory artefact that can introduce serious problems in diagnosis and treatment in patients with low platelet count." | ( Grgicevic, D; Jaksić, B; Putarek, K; Sarlija, D; Soldo, D; Vuk, T, 1997) |
| "Thrombocytopenia is considered a relative contraindication to the administration of regional anesthesia." | ( Beilin, Y; Comerford, M; Zahn, J, 1997) |
| "Thrombocytopenia is a common finding in infection with equine infectious anaemia virus (EIAV), a lentivirus with some homology to human immunodeficiency virus (HIV)." | ( Crawford, TB; Oaks, JL; Tornquist, SJ, 1997) |
| "Leukopenia and thrombocytopenia are observed mostly as a side effect of therapy, particularly with use of immunosuppressive drugs." | ( Ammirati, M; Gruenstein, S; Kim, P; Korelitz, BI; Lipsey, L; Schwarz, S; Wisch, N; Zlatanic, J, 1997) |
| "Hereditary macrothrombocytopenia is a hallmark of Wistar Furth (WF) rats." | ( Arnold, JT; Barrie, RJ; Hutson, NK; Jackson, CW; Murti, AK; Pestina, TI; Stenberg, PE; Steward, SA, 1998) |
| "Heparin-induced thrombocytopenia is an uncommon but potentially serious, and sometimes lethal, complication of heparin therapy." | ( Gupta, AK; Kovacs, MJ; Sauder, DN, 1998) |
| "Heparin-induced thrombocytopenia is an increasingly common side effect associated with heparin usage." | ( Bakhos, M; Ero, M; Haas, S; Herbert, JM; Jeske, WP; Szatkowski, E; Walenga, JM, 1997) |
| "Heparin-induced thrombocytopenia is a relatively common complication of heparin therapy that can result in thrombosis and subsequent limb loss or death, necessitating use of alternative anticoagulants." | ( Deeb, GM; Gitlin, SD; Schmaier, AH; Yann, C, 1998) |
| "Although thrombocytopenia is more frequent with teicoplanin, it is reversible and seldom seen at standard doses." | ( Wilson, AP, 1998) |
| "Severe immune thrombocytopenia is an idiosyncratic complication of quinine therapy." | ( Berndt, MC; Burgess, JK; Chesterman, CN; Chong, BH; Dawes, I; Lopez, JA, 1998) |
| "Thrombocytopenia is associated with bleeding, which may be serious and life threatening." | ( Biemond, BJ; de Groot, PG; Friederich, PW; Harris, R; Heijnen, HF; Levi, M; Levin, J; Middleton, S; ten Cate, JW; Wu, YP, 1999) |
| "MAOI causing thrombocytopenia is reviewed and the prescription of tranylcypromine to patients with previous substance abuse is discussed." | ( Albrecht, J; Szelényi, A, 1998) |
| "Thrombocytopenia is frequently reported in type 2B von Willebrand disease (vWD), and thought to be related to the abnormally high affinity of 2B von Willebrand factor (vWF) for platelet GPIb-IX." | ( Casonato, A; De Marco, L; Girolami, A; Pontara, E; Rossi, C; Steffan, A; Zucchetto, A, 1999) |
| "Heparin-induced thrombocytopenia is a relatively uncommon but severe side-effect of heparin therapy." | ( Harenberg, J; Hoffmann, V; Huhle, G; Malsch, R; Song, XL; Wang, LC, 1999) |
| "Thrombocytopenia is a frequent complication of cancer and constitutes an absolute contraindication for chemotherapy." | ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| "Because severe thrombocytopenia is not commonly seen with standard chemotherapy regimens, clinical studies examining c-mpl ligands for their ability to ameliorate chemotherapy-induced thrombocytopenia will focus on treatment of acute leukemias and bone marrow transplantation." | ( Hoelzer, D; Hofmann, WK; Ottmann, OG, 1999) |
| "Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy." | ( Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Snyder, J; Wood, L, 1999) |
| "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy." | ( Black, MD; Edgell, D; Leaker, MT; Noel, D; Saxon, BR, 1999) |
| "Thrombocytopenia is a substantial clinical problem for patients with myelodysplastic syndromes (MDS)." | ( Hellström-Lindberg, E; Kanter-Lewensohn, L; Nichol, J; Ost, A, 1999) |
| "falciparum." | ( Bhoi, S; Kakar, A; Kakar, S; Prakash, V, 1999) |
| "Thrombocytopenia is a significant problem in the treatment of cancer." | ( Ashby, M; Broxmeyer, HE; Bueso-Ramos, C; Edwards, CL; Freedman, RS; Gershenson, D; Jones, D; Kavanagh, JJ; Kudelkà, AP; Vadhan-Raj, S; Verschraegen, CF, 2000) |
| "Heparin-induced thrombocytopenia is one of the most difficult problems facing clinicians today." | ( Lewis, BE; Messmore, HL; Pifarre, R; Walenga, JM; Wallis, DE, 1999) |
| "Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a patient treated with c7E3 Fab." | ( Fischer, Y; Reinauer, H; Steiner, S; Stiegler, H; Strauer, BE, 2000) |
| "Neutropenia and thrombocytopenia are well-known complications of antipsychotic drug therapy." | ( Caraco, Y; Gural, A; Hirshberg, B, 2000) |
| "Heparin-induced thrombocytopenia is caused by the formation of antibodies that bind to specific complexes of platelet factor 4 (PF4) and heparin." | ( Horsewood, P; Kelton, JG, 2000) |
| "Drug-induced thrombocytopenia is a phenomenon that causes significant morbidity and mortality among patients." | ( Gandhi, PJ; Patnode, NM, 2000) |
| "In conclusion, thrombocytopenia is a frequent finding in patients on dialysis." | ( Ando, M; Iwamoto, Y; Nihei, H; Suda, A; Tsuchiya, K, 2001) |
| "Alloimmune thrombocytopenia is a serious fetal disorder resulting from platelet-antigen incompatibility between the mother and the fetus." | ( Delmis, J; Mayer, D; Pfeifer, D; Radoncić, E, 2000) |
| "Thrombocytopenia is generally of central origin in MDS, but can be due to peripheral platelet destruction in some cases." | ( Bauters, F; Bourgeois, E; Caulier, MT; Dupriez, B; Fenaux, P; Rose, C, 2001) |
| "Thrombocytopenia is a rare finding in patients with WG." | ( Gross, WL; Meyer, MF; Schatz, H; Schnabel, A, 2001) |
| "Heparin-induced thrombocytopenia is a prothrombotic drug reaction caused by platelet-activating antibodies that recognize complexes of platelet factor 4 and heparin." | ( Kelton, JG; Warkentin, TE, 2001) |
| "Heparin-induced thrombocytopenia is an immunologic complication of heparin therapy with potentially serious venous and arterial thrombotic sequelae." | ( Aida, H; Aoki, Y; Ohki, I; Tanaka, K, 2001) |
| "Thrombocytopenia is a major clinical problem caused by chemotherapy and radiotherapy." | ( Dziambor, H; Hager, ED; Höhmann, D; Strama, H; Winkler, P, 2001) |
| "Thrombocytopenia is a common disorder in dogs and development of an objective diagnostic assay to measure platelets newly released from bone marrow into the blood would provide a noninvasive way to predict megakaryocytopoiesis." | ( Smith, R; Thomas, JS, 2002) |
| "Acute thrombocytopenia is a recognized complication of treatment with GPIIb/IIIa inhibitors whose cause is not yet known." | ( Aster, RH; Bougie, DW; Curtis, BR; Levine, S; Lind, RN; Malik, M; Pereira, J; Wilker, PR; Wuitschick, ED, 2002) |
| "Thrombocytopenia is a relatively common side effect observed during glycoprotein (GP) IIb/IIIa antagonist therapy." | ( Barrett, YC; Billheimer, JT; Cromley, DA; Daly, RN; Ebling, W; He, B; Hollis, GF; Hua, TA; Kieras, CJ; Pedicord, DL; Pieniaszek, HJ; Rossi, RJ; Seiffert, D; Sferruzza, A; Stein, RB; Stern, AM; Wynn, R, 2003) |
| "However, thrombocytopenia is a problem in heavily pretreated patients." | ( Fujiwara, K; Ishikawa, H; Kohno, I; Suzuki, S; Tanaka, Y, 2002) |
| "Thrombocytopenia is a poor prognostic indicator in the myelodysplastic syndromes (MDS)." | ( Chan, G; DiVenuti, G; Miller, K, 2002) |
| "Grade III-IV thrombocytopenia is common in accelerated phase CML and may be a marker for the inability to achieve cytogenetic response using single agent imatinib mesylate." | ( Berkowitz, LR; Dunphy, CH; Hall, MD; Hogan, C; Koehler, J; Mitchell, BS; Orlowski, RZ; Shea, TC; van Deventer, HW, 2002) |
| "Thrombocytopenia is a major cause of bleeding episodes at all ages." | ( Choudhry, VP, 2002) |
| "Pseudothrombocytopenia is usually associated with blood specimens anticoagulated with ethylenediamine tetraacetic acid (EDTA) or other anticoagulants." | ( Allebes, W; de Keijzer, MH; Simon, A; van Berkel, Y; van der Meer, W, 2002) |
| "Cyclic thrombocytopenia is a rare disorder characterized by periodic platelet count fluctuations of unknown aetiology." | ( Füreder, W; Geissler, K; Krebs, M; Kyrle, PA; Lechner, K; Mitterbauer, G; Panzer, S; Simonitsch-Klupp, I; Sperr, WR; Thalhammer, R, 2002) |
| "Severe thrombocytopenia is common in isolated falciparum and mixed falciparum/vivax malaria, but is very rare in isolated P." | ( Gupta, AK; Makkar, RP; Monga, A; Mukhopadhyay, S, 2002) |
| "Thrombocytopenia is generally seen as a complication in typhoid fever." | ( Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Sevinc, A, 2003) |
| "Because thrombocytopenia is common in patients with acute liver failure (ALF), we measured TPO concentrations (normal TPO range, 31 to 136 pg/mL) in 51 patients with ALF to determine if low levels were associated with thrombocytopenia." | ( Balko, J; Harrison, ME; Lee, WM; Schilsky, M; Schiødt, FV; Thornton, A, 2003) |
| "Thrombocytopenia is observed with a frequency of up to 2% in patients treated with glycoprotein (GP) IIb/IIIa antagonists." | ( Billheimer, JT; Breth, L; Dicker, I; Hollis, GF; O'Neil, K; Pedicord, DL; Seiffert, D; Stern, AM; Wynn, R, 2003) |
| "Immune thrombocytopenia is a common complication of therapy with a large number of drugs." | ( Ahmadi, Z; Asvadi, P; Chong, BH, 2003) |
| "Thrombocytopenia is a serious complication well described with the use of the prototype GPIIb/IIIa inhibitor abciximab." | ( Khaykin, Y; Madan, M; Paradiso-Hardy, FL, 2003) |
| "Thrombocytopenia is an important and common hematological abnormality in patients with HIV-1/HCV coinfection." | ( Candela, M; Corti, ME; Daruich, J; Ferraina, P; Pérez Bianco, R; Suárez Anzorena, F; Tezanos Pinto, M; Villafañe, MF, 2003) |
| "Thrombocytopenia is well known to be one of the clinical manifestations of chronic graft-versus-host disease (cGVHD)." | ( Akiyama, T; Chiba, H; Hirayama, Y; Kato, J; Kuroda, H; Kusakabe, T; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Tsuji, Y, 2003) |
| "Thrombocytopenia is a frequent hematological complication in patients with liver cirrhosis, but its pathogenesis is not clearly understood." | ( Franchini, M, 2003) |
| "Thrombocytopenia is a common finding in patients in the intensive care unit receiving continuous renal replacement therapy (CRRT)." | ( Bellomo, R; Mulder, J; Silvester, W; Tan, HK, 2003) |
| "Thrombocytopenia is recognized as one of the most common complications when the patients with severe heart failure are treated with cardiotropic phosphodiesterase (PDE)-3 inhibitors." | ( Goto, S; Handa, S; Hoshiba, Y; Ikeda, Y; Kumagai, A; Sadiq, A; Tamura, N; Tanabe, T; Yoshida, M, 2003) |
| "Thrombocytopenia is typically rapid in onset and antibody mediated." | ( Abrams, CS; Cines, DB, 2004) |
| "Thrombocytopenia is recognized as a potential adverse effect in patients treated with glycoprotein IIb/IIIa inhibitors." | ( Fahdi, IE; Garza-Arreola, L; Ghani, M; Hennebry, T; Sadanandan, S; Saucedo, JF, 2004) |
| "Drug-induced thrombocytopenia is a serious, but rare, side-effect of treatment with a number of drugs." | ( Andersohn, F; Aslan, T; Garbe, E; Kiesewetter, H; Meyer, O; Salama, A, 2004) |
| "Neutropenia and thrombocytopenia are usually managed by IFN or PEG-IFN dose reduction; the role of hematopoietic growth factors to ameliorate these side effects needs further evaluation, but some studies suggest granulocyte colony-stimulating factor (G-CSF) may be useful in the management of IFN/PEG-IFN-associated neutropenia." | ( Afdhal, NH, 2004) |
| "Thrombocytopenia is a possible complication of treatment with glycoprotein (GP) IIb/IIIa antagonists during percutaneous coronary interventions, but it is not clear whether different GP IIb/IIIa inhibitors carry a different risk of thrombocytopenia, and its relation to clinical outcome is unknown." | ( Ardissino, D; Brennan, DM; Buratti, S; Menozzi, A; Merlini, PA; Moliterno, DJ; Rossi, M; Topol, EJ, 2004) |
| "Severe thrombocytopenia is a life-threatening condition." | ( Arnold, DM; Christjanson, L; Smaill, F; Walker, I; Warkentin, TE, 2004) |
| "Heparin-induced thrombocytopenia is a serious complication of heparin therapy, and it remains a therapeutic challenge in the subset of patients requiring cardiopulmonary bypass." | ( Aranki, SF; Fitzgerald, D; Gasparovic, H; Nathan, NS, 2004) |
| "Strong thrombocytopenia is observed during acute infection with Trypanosoma cruzi, the parasitic protozoan agent of American trypanosomiasis or Chagas' disease." | ( Campetella, O; Leguizamón, MS; Mucci, J; Tribulatti, MV; Van Rooijen, N, 2005) |
| "Acute, profound thrombocytopenia is a rare complication of glycoprotein IIb/IIIa inhibitor therapy characterized by a precipitous decline in platelet count to <20 x10(3)/mm3 within 24 hours of therapy." | ( Barcelona, RA; Coons, JC; Freedy, T; Hagerty, MF, 2005) |
| "Thrombocytopenia is one of the major side effects in young thalassaemics and necessitates frequent close monitoring of blood counts but its resolution after discontinuation and absence of clinical evidence of bleeding does not preclude its use." | ( Chandra, J; Naithani, R; Sharma, S, 2005) |
| "Thrombocytopenia is not a common adverse effect of beta-antagonist therapy." | ( Jenkins, JK; Stamm, PL; Vigrass, HG, 2005) |
| "Thrombocytopenia is rapid in onset and antibody mediated." | ( Erkoc, R; Eryonucu, B; Tuncer, M, 2004) |
| "Thrombocytopenia is a common finding in falciparum infection but rare in Plasmodium vivax." | ( Aggarwal, A; Rath, S, 2005) |
| "Thrombocytopenia is a common finding in malaria." | ( Jadhav, UM; Kadam, NN; Patkar, VS, 2004) |
| "Although absence of thrombocytopenia is uncommon in malaria, its presence is not a distinguishing feature between the two types." | ( Jadhav, UM; Kadam, NN; Patkar, VS, 2004) |
| "Thrombocytopenia is no longer essential for the diagnosis of HIT, since a 50% drop in the platelet count may be a more specific indicator." | ( Almahameed, A; Bartholomew, JR; Begelman, SM, 2005) |
| "Thrombocytopenia is a common condition in the critical care setting." | ( Blumenberg, D; Heuer, L, 2005) |
| "Drug-induced thrombocytopenia is common, but most previous reports do not present evidence for drugs as a definite or probable cause of the thrombocytopenia." | ( Nomura, S, 2005) |
| "Thrombocytopenia is a rarely reported hematologic adverse consequence of thalidomide therapy." | ( Brouwers, JR; Duyvendak, M; Kingma, BJ; Naunton, M, 2005) |
| "In this patient, thrombocytopenia is initially thought to be associated with active SLE involving major organ." | ( Chang, HK, 2005) |
| "Thrombocytopenia is frequently found in patients with the antiphospholipid syndrome (APS), yet data concerning clinical associations of thrombocytopenia in patients with APS are still scarce." | ( Blank, M; Fraser, A; Krause, I; Lorber, M; Rovensky, J; Shoenfeld, Y; Stojanovich, L, 2005) |
| "Thrombocytopenia is one of the common manifestations of systemic lupus erythematosus (SLE)." | ( Bae, YD; Choi, HJ; Lee, EB; Lee, JC; Shin, KC; Song, YW, 2005) |
| "Although thrombocytopenia is a recognized side effect of interferon therapy, this very dangerous complication has not been previously reported using interferon for the Kasabach-Merritt syndrome." | ( de la Hunt, MN, 2006) |
| "Heparin-induced thrombocytopenia is a potentially limb- and life-threatening response to heparin exposure." | ( Gurley, WQ; Kirklin, JK; Lell, WA; Nielsen, VG; Pereira, SJ; Steenwyk, BL, 2006) |
| "Thrombocytopenia is common in patients with lung diseases." | ( Fok, FT; Hon, KL; Xiao, da W; Yang, J; Yang, M, 2006) |
| "Familial macrothrombocytopenias are a group of rare autosomal dominant platelet disorders including many syndromes in particular the May-Hegglin anomaly." | ( Bardet, V; Berda-Haddad, Y; Bernit, E; Camoin, L; Difeo, A; Ebbo, M; Favier, R; Harle, JR; Heudier, P; Kaplanski, G; Mazodier, K; Schleinitz, N; Veit, V, 2006) |
| "Thrombocytopenia is a common occurrence in critical illness, reported in up to 41% of patients." | ( Almahameed, A; Napolitano, LM; Nasraway, SA; Warkentin, TE, 2006) |
| "We conclude that thrombocytopenia is the dose limiting toxicity for boronated porphyrins in mammals and suggest that these effects may be due to the porphyrin, not the borane or carborane." | ( Bollen, AW; Deen, DF; Kahl, SB; Koo, MS; Lamborn, KR; Ozawa, T; Santos, RA, 2007) |
| "Thrombocytopenia is a common side effect of chemotherapy, responsible for increased risk of bleeding and delay of treatment schedules in cancer patients." | ( Bartucci, M; De Maria, R; Martinetti, D; Peschle, C; Signore, M; Zeuner, A, 2007) |
| "Thrombocytopenia is an uncommon but potentially life threatening complication of certain anti-tubercular drugs and is characterized by rapid destruction of platelets whenever an offending drug is taken by a susceptible person." | ( Garg, R; Gupta, V; Mehra, S; Prasad, R; Singh, R, 2007) |
| "Pseudothrombocytopenia is observed occasionally in post-cardiac surgical patients." | ( Keogh, BE; Nair, SK; Petko, M; Shah, R, 2007) |
| "Thrombocytopenia is not listed as one of the main side effects of PPI therapy." | ( Bratcher, J; Dotan, E; Katz, R; Liebman, M; Panagopoulos, G; Spaccavento, C; Wasserman, C, 2007) |
| "Dilutional thrombocytopenia is frequently seen in the fetus following red blood cell transfusion alone." | ( de Haan, TR; Kroes, AC; Oepkes, D; Porcelijn, L; van den Akker, ES; Walther, FJ, 2008) |
| "Thrombocytopenia is a major factor leading to this complication, but the bleeding tendency of FA patients often exceeds what one might expect based on their platelet counts." | ( Ebell, W; Grossmann, R; Hanenberg, H; Holzhauer, S; Schindler, D; Sitaru, AG; Walter, U; Wirbelauer, J, 2007) |
| "Thrombocytopenia is associated with an increased risk for adverse cardiac events and bleeding in patients presenting with acute coronary syndromes (ACS) treated with unfractionated heparin (UFH)." | ( Antman, EM; Bradner, JE; Gibson, CM; Giugliano, RP; Jang, IK; Morrow, DA; Qin, J; Scirica, B; Shui, A; Wiviott, SD; Yeh, RW, 2007) |
| "Thrombocytopenia is an indicator of severe disease and risk of bleeding." | ( Chierakul, W; Day, NP; Limpaiboon, R; Opartkiattikul, N; Peacock, SJ; Phimda, K; Suputtamongkol, Y; Tientadakul, P; White, NJ; Wuthiekanun, V, 2008) |
| "Acute profound thrombocytopenia is a serious complication of glycoprotein IIb/IIIa inhibitor therapy characterized by a precipitous decline in platelet count to <20 x 10(9)/l within few hours of therapy initiation." | ( Agnelli, D; Ottani, F, 2008) |
| "Thrombocytopenia is a common haematological abnormality and no simple diagnostic test is available to diagnose thrombocytopenia pathogenesis." | ( Amengual, MJ; Monteagudo, M; Muñoz, L; Roig, I; Soler, JA; Tolosa, C, 2008) |
| "Heparin-induced thrombocytopenia is an immunologically mediated syndrome that is associated with potentially life-threatening arterial and venous thrombosis." | ( Bracey, AW; Cooper, JR; Frazier, OH; Pinto, K; Wadia, Y, 2008) |
| "Thrombocytopenia is a critical problem that occurs in many hematologic diseases, as well as after cancer therapy and radiation exposure." | ( Blumberg, N; Francis, CW; Gertz, JM; O'Brien, JJ; Palis, J; Phipps, RP; Seweryniak, KE; Spinelli, SL; Taubman, MB; Tober, J, 2008) |
| "Drug-induced thrombocytopenia is an uncommon but serious side effect of many drugs including antituberculosis drugs." | ( Kant, S; Mahajan, V; Natu, NK, 2008) |
| "Thrombocytopenia is the most common hematological disturbance seen in malarial infection." | ( Abdalla, DS; Araujo, CF; Lacerda, MV; Lima, ES, 2008) |
| "Heparin-induced thrombocytopenia is a devastating, life-threatening, immune-mediated complication of therapy with unfractionated heparin, and less frequently, with low molecular weight heparin." | ( Taimeh, Z; Weksler, B, 2010) |
| "Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions." | ( Buck, LM; Kline, RM, 2009) |
| "Thrombocytopenia is observed frequently, is multi-factorial in etiology, and may result in significant limitations on interventional and therapeutic options." | ( McHutchison, JG; Patel, K; Tillmann, HL, 2009) |
| "Thrombocytopenia is a condition of unusually low level of platelets in blood, resulting from an imbalance between the production and destruction of platelets, and is associated with aplastic anemia, myelodysplasia, and idiopathic thrombocytopenic purpura (ITP)." | ( Dusheiko, G, 2009) |
| "Thrombocytopenia is a frequent symptom and clinical challenge in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)." | ( Aivado, MA; Bruns, I; Erickson-Miller, CL; Kawahara, M; Luciano, JP; Parekh, S; Steidl, U; Verma, A; Will, B, 2009) |
| "The thrombocytopenia is not intrinsic to defects at the level of hematopoietic progenitor cells but is associated with a microenvironmental abnormality." | ( Bronson, RT; Burzenski, LM; Ceglarek, U; Chase, TH; Donahue, LR; Foreman, O; Gott, B; Harris, B; Italiano, JE; Johnson, KR; Lane, P; Lyons, BL; Shultz, LD; Thiery, J; Thon, JN; Wittenburg, H, 2010) |
| "Macrothrombocytopenia is a rare condition where large, circulating platelets ranging between approximately 5 and 20 microm are found (typically platelets size range from 1." | ( Meiring, JH; Oberholzer, HM; Pretorius, E; van der Spuy, WJ, 2009) |
| "Thrombocytopenia is a major adverse effect of several drug treatments." | ( Choi, JC; Kang, JH; Kang, SY; Lee, JS, 2010) |
| "Thrombocytopenia is one of the most frequent challenges faced in patients with chronic liver diseases." | ( Saif, MW, 2010) |
| "The thrombocytopenia is typically moderate, with a median platelet count nadir of approximately 50 to 60 x 10(9) platelets/L." | ( Ortel, TL, 2009) |
| "Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings." | ( Cook, RJ; Greinacher, A; Marder, VJ; Warkentin, TE, 2010) |
| "Thrombocytopenia is known to occur following the administration of various drugs, including heparin and glycoprotein IIb/IIIa inhibitors." | ( Jafary, FH; Rahman, N, 2010) |
| "Fetal alloimmune thrombocytopenia is a potentially lethal condition, but early detection and prevention lead to successful outcome in most cases." | ( Barini, R; Barjas-Castro, ML; Castro, V; Couto, E; Martinelli, BM; Nomura, ML; Passini Júnior, R, 2010) |
| "Thrombocytopenia is not a well-known adverse effect of this medication." | ( Mohamed, BP; Peer Mohamed, B; Prabhakar, P, 2009) |
| "Thrombocytopenia is a common complication in patients receiving continuous veno-venous hemofiltration (CVVH) in the intensive care unit." | ( He, C; Li, H; Liang, X; Liang, Y; Liu, S; Ma, J; Shi, W; Su, Y; Tao, Y; Xia, Y; Xu, L; Ye, H; Ye, Z; Zhang, B, 2010) |
| "LEV-induced thrombocytopenia is a rare but reversible complication of LEV therapy." | ( Goyal, MK; Sahaya, K; Sarwal, A; Singh, NN, 2010) |
| "Thrombocytopenia is a significant risk for patients with chronic HCV infection and a common side-effect of treatment with pegylated (PEG) interferon (IFN)." | ( Grotzinger, K; Poordad, F; Sullivan, J; Theodore, D, 2011) |
| "Drug-induced thrombocytopenia is a clinically important adverse drug event involving many drugs including hydantoins." | ( Manor, SM; Ranzino, AM; Sorrells, KR, 2010) |
| "Thrombocytopenia is a common feature of myelodysplastic syndromes (MDS)." | ( Li, Z; Wang, J; Wang, S; Yi, Z, 2011) |
| "Heparin induced thrombocytopenia is a serious complication of heparin therapy that has a high levels of morbidity and mortality due to thrombotic complications." | ( Bülbül, Y; Korkmaz, A; Ozlü, T; Ozsu, S; Oztuna, F, 2011) |
| "Thrombocytopenia is commonly seen in Plasmodium vivax malaria, but its prognostic value has not been addressed in children." | ( Acharya, J; Chahar, CK; Chahar, S; Das, A; Garg, S; Khatri, N; Khatri, PC; Kochar, A; Kochar, DK; Kochar, SK; Middha, S; Pakalapati, D; Sengar, GS; Tanwar, G; Tanwar, GS, 2012) |
| "Cefepime-induced thrombocytopenia is a rare adverse event (incidence <1." | ( Aziz, NA; Chong, CP; Lim, PP, 2011) |
| "Thrombocytopenia is frequently observed in intensive care medicine, and it is associated with increased mortality." | ( Neef, M; Petros, S; Weidhase, L, 2011) |
| "Thrombocytopenia is a major haematological disorder of cirrhosis with unclear pathogenesis." | ( Kalambokis, GN; Mouzaki, A; Rodi, M; Tsianos, EV, 2012) |
| "Pseudothrombocytopenia is an ex vivo thrombocytopenia, counted by an automated cell counter, but not configured by microscopic examination of a well prepared blood smear." | ( Mallick, J; Mandal, PK; Sinha, SK, 2011) |
| "Thrombocytopenia is a well-known side effect of treatment with this class of drugs and is caused by Abs, often naturally occurring, that recognize α(IIb)/β(3) in a complex with the drug being administered." | ( Aster, RH; Bougie, DW; Rasmussen, M; Zhu, J, 2012) |
| "Thrombocytopenia is a well-known complication of GPIIb/IIIa inhibitors." | ( Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S, 2012) |
| "Thrombocytopenia is a common finding in patients with chronic liver disease related to hepatitis C virus (HCV) infection." | ( Naveau, S; Perlemuter, G; Voican, CS, 2012) |
| "Thrombocytopenia is a well-documented adverse reaction of sunitinib." | ( Albersen, A; Hamberg, P; Njo, T; Porcelijn, L; Schilders, J; Zuetenhorst, H, 2013) |
| "A mild thrombocytopenia is relatively frequent during pregnancy and has generally no consequences for either the mother or the fetus." | ( Gernsheimer, T; James, AH; Stasi, R, 2013) |
| "Heparin-induced thrombocytopenia is a reaction associated with the use of this drug." | ( Cegarra-Sanmartín, V; Galán, J; Moral, MV; Muñoz, C; Paniagua, P, 2013) |
| "Thrombocytopenia is sometimes observed during linezolid therapy." | ( Hatakeyama, S; Hisaka, A; Moriya, K; Nukui, Y; Okamoto, K; Suzuki, H; Yamamoto, T; Yata, N; Yotsuyanagi, H, 2013) |
| "Thrombocytopenia is caused by immune reactions elicited by diverse drugs in clinical practice." | ( Choi, PY; Chong, BH; Khachigian, L; Perdomo, J, 2013) |
| "Persistent thrombocytopenia is not a feature of dengue fever." | ( Hamide, A; Sivamani, K; Verma, SP; Wadhwa, J, 2013) |
| "Thrombocytopenia is a cirrhosis surrogate which is associated with hepatocellular carcinoma (HCC) development." | ( Carr, BI; Guerra, V, 2013) |
| "Thrombocytopenia is a common complication in the intensive care unit (ICU), but the incidence of drug-induced thrombocytopenia (DIT) is not well defined." | ( Cossu, AP; De Giudici, LM; Finco, G; Mura, P; Musu, M, 2014) |
| "Immune thrombocytopenia is an autoimmune-mediated disorder and the treatment strategies were directed mainly to suppression of the immune system or to removal of the spleen as a place of thrombocyte destruction." | ( Bussel, JB; Izak, M, 2013) |
| "Thrombocytopenia is often observed after yttrium-90 radioembolization (RE)." | ( Banerjee, A; Lam, MG; Louie, JD; Sze, DY, 2014) |
| "Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy." | ( Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY, 2014) |
| "Vancomycin-induced thrombocytopenia is a rare side effect of a commonly used drug that may cause life-threatening disease." | ( Rankin, I; Rowland, SP; Sheth, H, 2013) |
| "Thrombocytopenia is a known consequence of HIV infection, and decreased production of platelets has been previously implicated in the pathogenesis of platelet decline during asymptomatic infection." | ( Adams, RJ; Dorsey, JL; Lyons, CE; Mankowski, JL; Metcalf Pate, KA; Morrell, CN; Queen, SE, 2014) |
| "Heparin-induced thrombocytopenia is a potentiallylife-threatening complication of heparin or low-molecular-weight heparin administration." | ( Gevaert, A; Smets, H; Vercauteren, R, 2013) |
| "Inherited thrombocytopenias are heterogeneous diseases caused by at least 20 genes playing different role in the processes of megakaryopoiesis and platelet production." | ( Cerqua, C; De Rocco, D; Goffrini, P; Meloni, F; Moraes, CT; Nicchia, E; Pastore, A; Pecci, A; Russo, G; Salviati, L; Savoia, A, 2014) |
| "Drug-induced thrombocytopenia is more frequently related to immune mechanisms, and the diagnosis is still largely made by exclusion of other causes and by correlation of timing of thrombocytopenia with the administration of drug." | ( Amorós, F; Enriquez, R; Millan, I; Redondo-Pachon, MD; Romero, A; Sirvent, AE, 2014) |
| "Heparin-induced thrombocytopenia is a serious complication of heparin use." | ( Ashton, RF; Cairns, BA; Charles, AG; Khoury, AI; Phillips, MR, 2014) |
| "Thrombocytopenia is an abnormally low number of platelets in the blood resulting from either too few platelets being produced or existing platelets being destroyed." | ( diZerega, GS; Maulhardt, HA; Peterson, KJ; Rodgers, KE, 2014) |
| "Profound thrombocytopenia is an uncommon but clinically important complication of glycoprotein IIb/IIIa inhibitors." | ( Bitsis, T; Charalabopoulos, K; Dimitrelos, I; Dimitriadis, D; Dimitriadis, G; Golias, C; Graidis, C; Tsiakou, A, 2014) |
| "Severe thrombocytopenia is a life-threatening side effect of interferon therapy that can lead to bleeding." | ( Hidaka, H; Jiang, W; Kitagawa, H; Koizumi, W; Nakazawa, T, 2014) |
| "Severe drug-induced thrombocytopenia is a well known but rare complication of quinine." | ( Samaranayake, CB; Yap, E, 2014) |
| "Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS)." | ( Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T, 2014) |
| "Thrombocytopenia is a major side effect of linezolid therapy." | ( Hirano, R; Ohnishi, M; Sakamoto, Y; Tachibana, N, 2014) |
| "Pseudothrombocytopenia is the detection of low platelet counts by an autoanalyser despite lack of shortage in platelets." | ( Canbek, TD; Kırlı, I; Sahin, C; Sozen, H, 2014) |
| "Anemia and thrombocytopenia are the main secondary effects." | ( Beauverd, Y; Samii, K, 2014) |
| "Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies." | ( Awni, W; Humerickhouse, R; Kaefer, A; Mensing, S; Noertersheuser, P; Xiong, H; Yang, J, 2014) |
| "Heparin-induced thrombocytopenia is a well-recognized complication of anticoagulation with heparin." | ( Caldwell, C; Fitzmaurice, M; Natividad, K; Pericleous, A; Plestis, KA; Sadek, M, 2014) |
| "Drug-induced thrombocytopenia is known to occur with beta-lactam medications, but often in the setting of prolonged use." | ( Ender, PT; Kazi, HA; Shaik, S, 2015) |
| "In patients, thrombocytopenia is correlated with an adverse outcome of pneumonia." | ( Brands, X; de Stoppelaar, SF; Roelofs, JJ; Schouten, M; Schultz, MJ; van den Boogaard, FE; van der Poll, T; van't Veer, C, 2015) |
| "Thrombocytopenia is a rare side effect of vancomycin, an antibiotic that is often used to treat Gram-positive bacterial infections." | ( Ejiofor, K; Khan, MS; Lobo, N; Thurairaja, R, 2015) |
| "Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis." | ( Artim-Esen, B; Diz-Küçükkaya, R; İnanç, M, 2015) |
| "Thrombocytopenia is a common finding during viral hemorrhagic fever, which includes hemorrhagic fever with renal syndrome (HFRS)." | ( Ahlm, C; Baudin, M; Connolly-Andersen, AM; Dunne, E; Hultdin, J; Kenny, D; Larsson, J; Lindahl, TL; Nilsson, S; Ramström, S; Sundberg, E, 2015) |
| "Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon." | ( Afdhal, NH; Campbell, FM; Dusheiko, GM; Elkashab, M; Giannini, EG; Iyengar, M; Muir, AJ; Reddy, KR; Romero-Gómez, M; Sigal, SH; Theodore, D; Vasey, SY; Vijayaraghavan, S, 2015) |
| "Thrombocytopenia is a significant problem in patients with relapsed or refractory multiple myeloma, precipitating a need for supportive platelet transfusions and necessitating decreases in delivered doses of chemotherapy." | ( Abayasekara, N; Berliner, N; Jeong, JY; Laubach, J; Levine, MS; Vanasse, GJ, 2015) |
| "Thrombocytopenia is a common problem in cancer patients." | ( Kuter, DJ, 2015) |
| "Thrombocytopenia is a frequent complication of viral infections; the underlying mechanisms appear to depend on the identity of the virus involved." | ( Fondevila, C; Gómez, RM; Meiss, R; Pozner, RG; Rivadeneyra, L; Schattner, M, 2015) |
| "Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and bleeding complications are a major cause of morbidity and mortality." | ( Kambhampati, S; Li, W; Morrone, K; Steidl, U; Verma, A; Will, B, 2016) |
| "Drug-induced thrombocytopenia is a rare but serious adverse event that has been associated with multiple drugs including β-lactams." | ( Brouillette, D; Nguyen, VD; Roy, R; Tourigny, JF, 2015) |
| "Thrombocytopenia is one of the most common side effects that are encountered during triple therapy." | ( Baysal, B; Danalioglu, A; Kayar, Y; Kocaman, O; Senturk, H, 2015) |
| "Neonatal thrombocytopenia is widespread in preterm and term neonates admitted to neonatal intensive care units, with up to one-third of infants demonstrating platelet counts <150 × 10(9)/L." | ( Bührer, C; Cremer, M; Dame, C; Kling, PJ; Sallmon, H, 2016) |
| "Thrombocytopenia is associated with poor prognosis and a distinct serum cytokine profile." | ( Atta, M; Bartzeliotou, A; Chondropoulos, S; Dimitriadis, G; Dimopoulou, I; Frantzeskaki, F; Gkirkas, K; Papanikolaou, N; Papassotiriou, I; Stamouli, M; Tsirigotis, P, 2016) |
| "Persistent thrombocytopenia is a common complication after allogeneic hematopoietic cell transplantation (HCT)." | ( Fuji, S; Fukuda, T; Inamoto, Y; Kim, SW; Kurosawa, S; Okinaka, K; Tanaka, T; Tanosaki, R; Yamashita, T, 2016) |
| "Anemia and thrombocytopenia are frequent clinical manifestations of myelofibrosis as well as important prognostic factors of the disease." | ( Cervantes, F; Correa, JG; Hernandez-Boluda, JC, 2016) |
| "Severe thrombocytopenia is the most common adverse reaction of sunitinib treatment in Japanese RCC patients." | ( Enokida, H; Fujisawa, M; Fukasawa, S; Fukunaga, K; Hara, I; Hashine, K; Hongo, F; Inoue, T; Kato, Y; Kitamura, H; Kubo, M; Low, SK; Matsuda, K; Matsuyama, H; Miki, T; Mushiroda, T; Nakanishi, H; Nishimura, K; Takahashi, A; Tanaka, T; Tatsugami, K; Tomita, Y; Uemura, H, 2016) |
| "Drug-associated thrombocytopenia is common and curable, but there were few reports about entecavir-associated thrombocytopenia." | ( Chen, L; Fan, X; Feng, P; Yang, J, 2016) |
| "Thrombocytopenia is the reduction in the number of blood -platelets, which may be caused by -several different conditions such as sepsis, disseminated intravascular -clotting, and large blood losses." | ( Cuman, RK; Danieletto, CF; Farah, GJ; Ferreira, GZ, 2017) |
| "Vancomycin-induced thrombocytopenia is a rare condition, which is also a significant disorder that demands attention and the rapid identification and replacement of the antimicrobial agent." | ( Cuman, RK; Danieletto, CF; Farah, GJ; Ferreira, GZ, 2017) |
| "Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonly, to low-molecular weight heparin." | ( Adams, DH; Evans, AS; Fischer, GW; Heller, J; Salter, BS; Trinh, MA; Weiner, MM, 2016) |
| "Animal models of thrombocytopenia are indispensable for evaluating the in vivo efficacy of hemostatic agents, cryopreserved platelets, and artificial platelets, but no large animal models are available." | ( Abe, T; Hanazono, Y; Hishikawa, S; Kono, S; Kunita, S; Ohnuki, T, 2016) |
| "Thrombocytopenia is a common, multifactorial, finding in ICU." | ( Artaud-Macari, E; Beduneau, G; Besnier, E; Buchonnet, G; Carpentier, D; Dehay, J; Girault, C; Grangé, S; Guerrot, D; Marchalot, A; Tamion, F, 2016) |
| "Inherited macrothrombocytopenia is a subgroup of thrombocytopenias, and is characterised by the presence of giant platelets and decreased platelet count with variable bleeding manifestations." | ( Ali, S; Ghosh, K; Shetty, S, 2016) |
| "Heparin-induced thrombocytopenia is caused by antibodies (Abs) specific to platelet factor 4 (PF4)/heparin complexes." | ( Asahara, T; Izumi, M; Izumi, Y; Jiuchi, Y; Kozuru, H; Kumagai, K; Mawatari, M; Migita, K; Motokawa, S; Osaki, M; Sakai, T; Shirakawa, A, 2016) |
| "Neonatal thrombocytopenia is common and is frequently seen in neonatal sepsis." | ( Kalra, K; Maria, A; Mittal, HG, 2016) |
| "Background Thrombocytopenia is common in sick neonates." | ( Bastian, TW; Chen, MJ; Connor, JR; Duck, KA; Georgieff, MK; Lanier, LM; Liu, ZJ; Michalopoulos, GC; Sola-Visner, MC, 2017) |
| "Thrombocytopenia is frequently encountered in infants with necrotizing enterocolitis (NEC)." | ( Garg, L; Maheshwari, A; MohanKumar, K; Namachivayam, K; Torres, BA, 2017) |
| "Thrombocytopenia is among the most important adverse effects of linezolid treatment." | ( Heo, YA; Higashi, Y; Holford, NHG; Kasai, H; Mizoguchi, A; Ogami, C; To, H; Tsuji, Y; Yamamoto, Y, 2017) |
| "Pseudothrombocytopenia is a rare phenomenon in laboratory explained by in vitro agglutination of platelets." | ( Boui, M; Jalal, Y; Titou, H, 2017) |
| "Thrombocytopenia is often caused by myelosuppression during chemotherapy." | ( Awataguchi, T; Hirakawa, H; Kadota, R; Kiba, T; Noguchi, N; Ota, N; Otomo, C; Saito, M; Saito, Y; Sakaguchi, M; Sato, M; Shoji, F; Suzuki, T; Takahashi, T; Watanabe, Y, 2017) |
| "Thrombocytopenia is a major side effect of a new class of anticancer agents that target histone deacetylase (HDAC)." | ( Ali, A; Bluteau, O; Debili, N; Diop, KM; Droin, N; Godin, I; Ishaq, R; Lapierre, V; Marolleau, JP; Matthias, P; Messaoudi, K; Muller, D; Palazzo, A; Pierron, G; Plo, I; Rameau, P; Raslova, H; Sliwa, D; Souquère, S; Thomas, SG; Vainchenker, W; Watson, SP, 2017) |
| "Thrombocytopenia is a life-threatening complication in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML)." | ( Afanasyev, B; Anagnostopoulos, A; Brenner, B; Denzlinger, C; Garcia-Delgado, R; Grosicki, S; Mittelman, M; Nagler, A; Platzbecker, U; Portella, MSO; Rossi, G; Selleslag, D; Wong, RSM; Zhu, Z, 2018) |
| "Spurious thrombocytopenia is a well-known phenomenon observed with the widespread use of hematology analyzers (HAs)." | ( Gao, L; Pan, S; Xu, J; Zhang, L, 2018) |
| "Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib." | ( Al-Fayoumi, S; Callahan, JA; Daly, R; Drummond, M; Gerds, AT; Gotlib, J; Granston, T; Gupta, V; Harrison, C; Hoffman, R; Jamieson, C; Mascarenhas, J; Mesa, R; Pristupa, A; Singer, JW; Stein, B; Szoke, A; Talpaz, M; Verstovsek, S, 2018) |
| "Heparin-induced thrombocytopenia is not uncommon in cardiac surgery." | ( Ascaso, M; Pereda, D; Quintana, E; Sandoval, E, 2019) |
| "Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock." | ( Aissaoui, N; Ajzenberg, N; Amour, J; Besnier, E; Borie, M; Bougon, D; Chardonnal, L; Delmas, C; Dessertaine, G; Girerd, N; Grisot, PH; Guidon, C; Helms, J; Kimmoun, A; Labro, G; Lamiral, Z; Levy, B; Medard, A; Megarbane, B; Mongardon, N; Nesseler, N; Ouattara, A; Oulehri, W; Pierrot, M; Renou, A; Rozec, B; Schmidt, M; Sonneville, R; Zogheib, E, 2018) |
| "Thrombocytopenia is a rare but potentially severe complication of tirofiban therapy." | ( Hohmann, C; Michels, G; Nettersheim, FS; Pfister, R, 2019) |
| "Here, we show that thrombocytopenia is caused by serotonin derived from mast cells (MCs), which are immune cells that are present in the perivascular space and are a major peripheral source of serotonin." | ( John, ALS; Mantri, CK; Masri, MFB; Rathore, APS, 2019) |
| "Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes and often induced by chemotherapy." | ( Huang, X; Liu, NW; Liu, S; Liu, WJ; Lu, Y; Wang, H; Wang, WD, 2019) |
| "Severe thrombocytopenia is an extremely rare complication of acute or chronic EBV infection." | ( Dhanorkar, M; Didel, S; Koganti, RA; Panigrahi, I, 2019) |
| "Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT)." | ( Bastida, JM; Bento, L; Bosch-Vilaseca, A; Cabrera, R; Chinea, A; De Miguel, C; Duarte, R; Espigado, I; Fernández-Avilés, F; García-Cadenas, I; García-Torres, E; González-Porras, JR; Gutiérrez, A; Herrera, C; López, J; Martínez-Muñoz, ME; Rivera, D; Roldán, E; Sampol, A; Solano, C; Valcárcel, D; Vaz, CP; Yáñez, L; Zudaire, T, 2019) |
| "Thrombocytopenia is commonly seen in patients receiving linezolid for >14 days." | ( Constantinescu, SN; Milosevic, TV; Payen, VL; Sonveaux, P; Tulkens, PM; Van Bambeke, F; Vertenoeil, G, 2019) |
| "Thrombocytopenia is a clinically important condition that can lead to several problems when not correctly diagnosed." | ( Mendes, CC; Silva, CF; Sousa, SM; Sousa, TM, 2020) |
| "Thrombocytopenia is a common complication among patients with chronic liver disease (CLD)." | ( Akahane, T; Fujinaga, Y; Ishida, K; Kaji, K; Kawaratani, H; Kaya, D; Kubo, T; Moriya, K; Namisaki, T; Sawada, Y; Shimozato, N; Takaya, H; Tsuji, Y; Yoshiji, H, 2020) |
| "Thrombocytopenia is usually associated with liver injury, elevated plasma aspartate aminotransferase and alanine aminotransferase levels, and high antiplatelet immunoglobulin (Ig) titers, although the mechanism behind these effects remains elusive." | ( Chang, HH; Hu, CT; Lien, TS; Lin, YY; Sun, DS, 2019) |
| "Thrombocytopenia is a serious adverse event that causes drug dose reduction or withdrawal." | ( Akahoshi, S; Beppu, T; Chiyonaga, S; Kinoshita, K; Motohara, T; Sato, N; Suyama, K; Yuki, H; Yuruki, H, 2019) |
| "Heparin-induced thrombocytopenia is a recognized concern in patients on extracorporeal life support." | ( Harrison, S; Hernandez, O; Kataria, V; Moore, L; Schwartz, G; Vaughan, N, 2020) |
| "Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma." | ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020) |
| "Thrombocytopenia is a common laboratory abnormality among critically ill patients under neurological intensive care unit (NCU) care." | ( Chun, YI; Kim, DW; Kim, W; Lee, CH, 2020) |
| "Thrombocytopenia is common in NCU patients." | ( Chun, YI; Kim, DW; Kim, W; Lee, CH, 2020) |
| "Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT)." | ( Fagioli, F; Girardi, K; Locatelli, F; Masetti, R; Pession, A; Prete, A; Quarello, P; Vendemini, F, 2020) |
| "Acute thrombocytopenia is a rare complication induced by the contrast medium." | ( Araki, SI; Chin-Kanasaki, M; Fujita, Y; Kume, S; Maegawa, H; Osawa, N; Sawai, K; Takeda, N; Yamahara, K; Yasuda-Yamahara, M, 2020) |
| "Thrombocytopenia is a common complication of influenza virus infection, and its severity predicts the clinical outcome of critically ill patients." | ( Barendrecht, A; Baumgärtner, W; Boes, M; Boons, GJ; Di Iorio, D; Huskens, J; Jansen, AJG; Kuiken, T; Low, HZ; Maas, C; Osterhaus, A; Rohn, K; Spaan, T; Stittelaar, K; Tieke, M; van Amerongen, G; van den Brand, J; van der Vries, E, 2020) |
| "Thrombocytopenia is common in advanced liver disease, and such patients frequently need invasive procedures." | ( Flamm, SL; Nilles, KM, 2020) |
| "Thrombocytopenia is one of the typical adverse events caused by linezolid (LZD)." | ( Hashinaga, K; Hiramatsu, K; Itoh, H; Iwao, M; Kadota, JI; Morinaga, Y; Suzuki, Y; Takumi, Y; Tanaka, R; Tatsuta, R, 2021) |
| "Linezolid-induced thrombocytopenia is rarely reported in liver transplant patients, especially in children." | ( Chen, L; Liu, Y; Lu, X; Qi, F; Zhang, B; Zhu, L, 2021) |
| "BACKGROUND Thrombocytopenia is a potentially treatment-limiting adverse event of particular interest with the PARP inhibitor niraparib." | ( Gabrail, N; Smith, C, 2020) |
| "Thrombocytopenia is a common major side-effect of cytotoxic cancer therapies." | ( Kheifetz, Y; Scholz, M, 2021) |
| "Preoperative thrombocytopenia is associated with inferior outcomes in surgical patients, though concurrent anemia may obfuscate these relationships." | ( Evans, KD; Hanson, AC; Kor, DJ; Matzek, LJ; Schulte, PJ; Warner, MA, 2021) |
| "Preoperative thrombocytopenia is associated with clinical outcomes in elective surgery, both in the presence and absence of concurrent anemia." | ( Evans, KD; Hanson, AC; Kor, DJ; Matzek, LJ; Schulte, PJ; Warner, MA, 2021) |
| "Delayed recovery of thrombocytopenia is a well-known complication after allogeneic HSCT." | ( Anak, S; Bayram, N; Bilgen, H; Elli, M; Nepesov, S; Özdilli, K; Şahin, Ş; Yaman, Y, 2021) |
| "Thrombocytopenia is common among patients with viral hepatitis, limiting the use of antiviral therapy." | ( Feng, Q; Hu, X; Li, N; Liu, A; Ma, S; Peng, J; Sheng, Z; Zhang, Y, 2021) |
| "Drug-induced thrombocytopenia is a rare but serious adverse reaction to sulfonamide antibiotics like Bactrim/Septra." | ( Fiore, B; Jahncke, A; Kay, V, 2022) |
| "Linezolid-induced thrombocytopenia is related to linezolid exposure, baseline platelet count and patient background." | ( Kasai, H; Kawasuji, H; Ogami, C; Takahashi, S; To, H; Tsuji, Y; Yamamoto, Y, 2021) |
| "Thrombocytopenia is independently related with increased mortality in severe septic patients." | ( Jiang, L; Liu, YJ; Mao, YF; Wang, Y; Xu, CF; Xu, DF; Zhu, XY, 2021) |
| "Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood." | ( Hirani, K; Kumar Seth, A; Maheshwari, R; Parmar, G; Sailor, G; Singh, R, 2021) |
| "Thrombocytopenia is a major complication in hematopoietic-acute radiation syndrome (H-ARS) that increases the risk of mortality from uncontrolled hemorrhage." | ( Calvi, LM; Catherman, SC; Kingsley, PD; Koniski, A; McGrath, KE; Medhora, M; Morrell, CN; Niswander, LM; Palis, J; Saunders, J; Ture, SK; Williams, JP, 2021) |
| "Macrothrombocytopenia is a common pathology of missense mutations in genes regulating actin dynamics." | ( Daimon, E; Okamoto, N; Shibukawa, Y; Thanasegaran, S; Yamazaki, N, 2021) |
| "Drug-induced immune thrombocytopenia is an isolated thrombocytopenia caused by accelerated platelet destruction from drug-dependent, platelet-reactive antibodies." | ( Kiliaki, S, 2023) |
| "Pseudo thrombocytopenia is the estimation of low platelet counts by a Haematology analyzer despite of shortage in platelets." | ( Hanif, B; Jabbar, J; Waseem, N, 2021) |
| "Thrombocytopenia is one of the most common hematological disease that can be life-threatening caused by bleeding complications." | ( Jiang, N; Li, H; Lin, J; Liu, S; Shen, X; Wang, L; Wu, JM; Wu, YS; Zeng, J, 2021) |
| "Thrombocytopenia is associated with a poor clinical status and adverse outcomes in patients with encephalitis of all causes." | ( Atam, V; Bhardwaj, A; Himanshu, D; Sawlani, KK; Verma, R; Verma, SP, 2022) |
| "Thrombocytopenia is one of its most common side effects often leading to severe complications." | ( Alaguero-Calero, M; Álvarez-Asteinza, C; Fernández, J; Maray, I; Rodríguez-Ferreras, A; Valledor, P, 2022) |
| "Radiation-induced thrombocytopenia is a common and life-threatening side effect of ionizing radiation (IR) therapy." | ( Huang, F; Huang, Q; Huang, X; Wang, L; Wu, J; Xiong, L; Ye, X; Zeng, J; Zhang, T, 2022) |
| "Thrombocytopenia is a common complication following hematopoietic stem cell transplantation (HSCT)." | ( Aksu, S; Büyükaşık, Y; Çınar, OE; Demiroğlu, H; Erdoğdu, B; Göker, H; Haznedaroğlu, İC; Karadeniz, M; Karataş, A; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Velet, M, 2022) |
| "Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis." | ( Berdeja, J; Bhagat, P; Braunschweig, I; Donnellan, WB; Fehn, K; Goldfinger, M; Gonzalez-Lugo, JD; Gritsman, K; Jasra, S; Kambhampati, S; Kazemi, M; Kim, M; Kornblum, N; Mantzaris, I; Pradhan, K; Remy, C; Shah, N; Shastri, A; Sica, RA; Steidl, U; Verma, A; Will, B; Yacoub, A, 2023) |
| "Drug-induced thrombocytopenia is a major limitation to adequate exposure to lomustine chemotherapy in recurrent glioblastoma." | ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "Drug-induced thrombocytopenia is a major limitation to adequate exposure to lomustine chemotherapy in recurrent glioblastoma." | ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "Drug-induced thrombocytopenia is a major limitation to adequate exposure to lomustine chemotherapy in recurrent glioblastoma." | ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "Hereditary thrombocytopenia is a heterogeneous group of congenital disorders with a wide range of symptoms depending on the severity of platelet dysfunction or thrombocytopenia." | ( Jeong, DJ; Kim, MJ; Kwon, S; Kwon, SR; Lee, DS; Lee, YE; Park, JH; Yun, J, 2022) |
| "Thrombocytopenia is a thrombopoietin (TPO)-related disorder with very limited treatment options, and can be lifethreatening." | ( Chen, J; Huang, F; Li, X; Liu, S; Luo, J; Mei, Q; Mo, Q; Ran, M; Wang, L; Wu, A; Wu, J; Yang, J; Zeng, J; Zhang, C; Zhang, T; Zou, W, 2023) |
| "Severe thrombocytopenia is rarely reported." | ( Chen, S; He, L; Huang, M; Tan, X; Zhang, X, 2023) |
| "Thrombocytopenia is the major concern with administration of linezolid for Gram-positive infections, whereas anemia is more common in patients with tuberculosis." | ( Cattaneo, D; Gervasoni, C; Marriott, DJ, 2023) |
| "Thrombocytopenia is a condition that causes a low amount of blood platelets." | ( Kim, DH; Kim, JH; Kim, SY; Oh, JH; Seo, EH, 2023) |
| "The inherited macrothrombocytopenias are rare disorders and the underlying cause can be identified in many cases but in some, this can remain enigmatic." | ( Cheves, TA; Ferreira, KA; Massingham, LJ; Montcrieff, C; Sweeney, JD, 2023) |
| "Drug-induced thrombocytopenia is associated with bleeding tendency and suggests the need for the immediate suspected drug withdrawal." | ( Fujii, R; Imai, Y; Muranaka, T; Nishiyama, N; Tanaka, M; Tomita, S; Uchitani, K, 2023) |
| "Thrombocytopenia is a common hematological disease caused by many factors." | ( Ge, G; Huang, F; Huang, Q; Lai, J; Li, Y; Ran, M; Tang, Y; Wu, A; Wu, J; Wu, Y; Xie, X; Yang, F; Zhu, L; Zou, W, 2023) |
| "Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy." | ( Jeong, JY; Kim, JW; Kim, MJ; Lee, S; Park, S; Quan, X; Shin, J; Yea, K, 2023) |
| "Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1)." | ( Behrendt, CE; Kasparian, S; Lavasani, S; Mortimer, JE; Nguyen, T; Patel, N; Pullarkat, V; Rainone, M; Sedrak, MS; Stewart, DB; Waisman, JR; Yuan, Y, 2023) |
| "Linezolid-induced thrombocytopenia is the main factor restricting the clinical application of linezolid." | ( Cao, Y; Chen, F; Duan, L; Feng, Z; Li, L; Lu, J; Shi, L; Sun, J; Tang, L; Xu, G; Xu, J; Xue, H; Yuan, Y; Zhou, Q; Zhuang, Z, 2023) |
| "Thrombocytopenia is a frequent complication in chronic lymphocytic leukemia (CLL)." | ( Honda, A; Jona, M; Kurokawa, M; Maki, H; Masamoto, Y; Morita, K; Nishikawa, M; Oyama, T; Yasunaga, M; Yatomi, Y, 2023) |
| "Thrombocytopenia is a critical complication after radiation therapy and exposure." | ( Chen, S; Dai, K; Hu, R; Khan, MS; Liu, C; Meng, F; Sun, C; Wan, J; Xia, Y; Yan, Y; Yang, M, 2024) |
| "Thrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality." | ( Al-Mashdali, AF; Bakr, MM; Gulied, A; Yassin, MA, 2023) |